This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Helpful information about getting started with PENBRAYA
PENBRAYA offers the broadest protection against the 5 leading meningococcal serogroups (A, B, C, W, and Y) in a single vaccine product
Learn about ACIP-recommended dosing for PENBRAYA
PENBRAYA can streamline vaccination for your patients and practice
References: 1. PENBRAYA [prescribing information]. New York, NY: Pfizer Inc.; 2023. 2. Vaccines and preventable diseases: meningococcal vaccination. Centers for Disease Control and Prevention. Last reviewed October 12, 2021. Accessed August 2, 2023.https://www.cdc.gov/vaccines/vpd/mening/index.html 3. Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571. 4. Recommended child and adolescent immunization schedule for children and adolescents aged 18 years or younger. Centers for Disease Control and Prevention. Published November 16, 2023. Accessed November 22, 2023. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 5. Collins J. Summary of EtR and proposed recommendations for Pfizer’s MenABCWY vaccine. Presented at: Advisory Committee on Immunization Practices (ACIP); October 25, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/04-Meningococcal-Collins-508.pdf
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.